Therefore, HO-1 inhibition or direct interference with its metabolites may evolve as new tactics in anticancer treatment of PaCa. This evidence concerns the gene HMOX1 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.